FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

原文始发于微信公众号(药时代):FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

欢迎参加2020中国NASH大会

FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

今天,美国食品药品监督管理局FDA)批准了Blueprint Medicines Corporation研发的Ayvakit(avapritinib)用于治疗无法切除(无法通过手术切除)或转移性胃肠道间质瘤(gastrointestinal stromal tumorGIST)的成年患者。GIST是胃肠道肿瘤的一种,最常见于胃或小肠,携带血小板衍生的生长因子受体α(PDGFRA)外显子18突变。该批准包括具有PDGFRA D842V突变的GIST,该突变是最常见的外显子18突变。作为一种激酶抑制剂Ayvakit通过抑制激酶而阻止癌细胞的生长。

热烈祝贺Blueprint Medicines Corporation

热烈祝贺Blueprint中国合作伙伴基石药业!

了解详情,请阅读FDA新闻稿!谢谢!

FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

FDA approves the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors

  • For Immediate Release:January 09, 2020

Today, the U.S. Food and Drug Administration approved Ayvakit (avapritinib) for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) gastrointestinal stromal tumor (GIST) – a type of tumor that occurs in the gastrointestinal tract, most commonly in the stomach or small intestine – harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation. This approval includes GIST that harbors a PDGFRA D842V mutation, which is the most common exon 18 mutation. Ayvakit is a kinase inhibitor, meaning it blocks a type of enzyme called a kinase and helps keeps the cancer cells from growing.

“GIST harboring a PDGFRA exon 18 mutation do not respond to standard therapies for GIST. However, today’s approval provides patients with the first drug specifically approved for GIST harboring this mutation,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in the FDA’s Center for Drug Evaluation and Research. “Clinical trials showed a high response rate with almost 85% of patients experiencing tumor shrinkage with this targeted drug.”

GISTs arise from specialized nerve cells found in the walls of the gastrointestinal tract. One or more mutations in the DNA of one of these cells may lead to the development of GIST. These cells aid in the movement of food through the intestines and control various digestive processes. More than half of GISTs start in the stomach. Most of the others start in the small intestine, but GISTs can start anywhere along the gastrointestinal tract. The activating mutations in PDGFRA have been linked to the development of GISTs, and up to approximately 10% of GIST cases involve mutations of this gene.

The FDA approved Ayvakit based on the results of a clinical trial involving 43 patients with GIST harboring a PDGFRA exon 18 mutation, including 38 patients with PDGFRA D842V mutation. Patients received Ayvakit 300 mg or 400 mg orally once daily until disease progression or they experienced unacceptable toxicity. The recommended dose was determined to be 300 mg once daily. The trial measured how many patients experienced complete or partial shrinkage (by a certain amount) of their tumors during treatment (overall response rate). For patients harboring a PDGFRA exon 18 mutation, the overall response rate was 84%, with 7% having a complete response and 77% having a partial response. For the subgroup of patients with PDGFRA D842V mutations, the overall response rate was 89%, with 8% having a complete response and 82% having a partial response. While the median duration of response was not reached, 61% of the responding patients with exon 18 mutations had a response lasting six months or longer (31% of patients with an ongoing response were followed for less than six months).

Common side effects for patients taking Ayvakit were edema (swelling), nausea, fatigue/asthenia (abnormal physical weakness or lack of energy), cognitive impairment, vomiting, decreased appetite, diarrhea, hair color changes, increased lacrimation (secretion of tears), abdominal pain, constipation, rash and dizziness. Ayvakit can cause intracranial hemorrhage (bleeding that occurs inside the skull) in which case the dose should be reduced, or the drug should be discontinued. Ayvakit can also cause central nervous system effects including cognitive impairment, dizziness, sleep disorders, mood disorders, speech disorders and hallucinations. If this happens, depending on the severity, Ayvakit should be withheld and then resumed at the same or reduced dose upon improvement or permanently discontinued.

Health care professionals should advise pregnant women that Ayvakit may cause harm to a developing fetus or newborn baby. Additionally, the FDA advises health care professionals to tell females of reproductive potential, and males with female partners of reproductive potential, to use effective contraception during treatment with Ayvakit and for six weeks after the final dose.

The FDA granted this applicationBreakthrough Therapydesignation, which expedites the development and review of drugs that are intended to treat a serious condition, when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapies. Ayvakit was also grantedFast Trackdesignation, which expedites the review of drugs to treat serious conditions and fill an unmet medical need. Ayvakit receivedOrphan Drugdesignation, which provides incentives to assist and encourage the development of drugs for rare diseases.

The FDA granted approval of Ayvakit to Blueprint Medicines Corporation.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

###

推荐阅读

FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

Fiona Yu专栏 | 沉寂多年的至尊辉瑞,还有并购以外的法宝吗?

2020-01-08

FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

Fiona Yu | 全球20大药企战略分析

2019-12-29

FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

Fiona Yu专栏 | BMS能否东山再起,靠的是O药还是Celgene

2020-01-03

FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

Fiona Yu专栏 | 靠兼并长大的赛诺菲(Sanofi),真正的绝招是啥?

2019-12-19

FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

Fiona Yu专栏 | 默沙东(MSD)能凭K药乘风破浪,霸王再起吗?

2019-12-13

FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

Fiona Yu专栏 | 从不合并的礼来(Lilly),单靠自己究竟能走多远?

2019-10-13 特稿

FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

Fiona Yu专栏 | 化工老大到药企龙头,从诺华Novartis)的转型经验你学到啥?

2019-11-27

FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

Fiona Yu专栏 | 武田Takeda)模式能否帮助亚洲药企杀入国际?

2019-11-20

FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

Fiona Yu专栏 | 百年药企强生(JNJ),能否再走百年?

2019-11-13

FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

Fiona Yu专栏 | 生物链上的江湖,新基(Celgene)是猎人还是猎物?

2019-10-28

FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

Fiona Yu专栏 | 走下神坛后,吉利德(Gilead)有何妙计翻身?

2019-10-22

FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法
FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

发布者:药时代,转载请首先联系contact@drugtimes.cn获得授权

发表评论

登录后才能评论
分享本页
返回顶部
FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法 | 药时代

FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

原文始发于微信公众号(药时代):FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

欢迎参加2020中国NASH大会

FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

今天,美国食品药品监督管理局FDA)批准了Blueprint Medicines Corporation研发的Ayvakit(avapritinib)用于治疗无法切除(无法通过手术切除)或转移性胃肠道间质瘤(gastrointestinal stromal tumorGIST)的成年患者。GIST是胃肠道肿瘤的一种,最常见于胃或小肠,携带血小板衍生的生长因子受体α(PDGFRA)外显子18突变。该批准包括具有PDGFRA D842V突变的GIST,该突变是最常见的外显子18突变。作为一种激酶抑制剂Ayvakit通过抑制激酶而阻止癌细胞的生长。

热烈祝贺Blueprint Medicines Corporation

热烈祝贺Blueprint中国合作伙伴基石药业!

了解详情,请阅读FDA新闻稿!谢谢!

FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

FDA approves the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors

  • For Immediate Release:January 09, 2020

Today, the U.S. Food and Drug Administration approved Ayvakit (avapritinib) for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) gastrointestinal stromal tumor (GIST) – a type of tumor that occurs in the gastrointestinal tract, most commonly in the stomach or small intestine – harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation. This approval includes GIST that harbors a PDGFRA D842V mutation, which is the most common exon 18 mutation. Ayvakit is a kinase inhibitor, meaning it blocks a type of enzyme called a kinase and helps keeps the cancer cells from growing.

“GIST harboring a PDGFRA exon 18 mutation do not respond to standard therapies for GIST. However, today’s approval provides patients with the first drug specifically approved for GIST harboring this mutation,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in the FDA’s Center for Drug Evaluation and Research. “Clinical trials showed a high response rate with almost 85% of patients experiencing tumor shrinkage with this targeted drug.”

GISTs arise from specialized nerve cells found in the walls of the gastrointestinal tract. One or more mutations in the DNA of one of these cells may lead to the development of GIST. These cells aid in the movement of food through the intestines and control various digestive processes. More than half of GISTs start in the stomach. Most of the others start in the small intestine, but GISTs can start anywhere along the gastrointestinal tract. The activating mutations in PDGFRA have been linked to the development of GISTs, and up to approximately 10% of GIST cases involve mutations of this gene.

The FDA approved Ayvakit based on the results of a clinical trial involving 43 patients with GIST harboring a PDGFRA exon 18 mutation, including 38 patients with PDGFRA D842V mutation. Patients received Ayvakit 300 mg or 400 mg orally once daily until disease progression or they experienced unacceptable toxicity. The recommended dose was determined to be 300 mg once daily. The trial measured how many patients experienced complete or partial shrinkage (by a certain amount) of their tumors during treatment (overall response rate). For patients harboring a PDGFRA exon 18 mutation, the overall response rate was 84%, with 7% having a complete response and 77% having a partial response. For the subgroup of patients with PDGFRA D842V mutations, the overall response rate was 89%, with 8% having a complete response and 82% having a partial response. While the median duration of response was not reached, 61% of the responding patients with exon 18 mutations had a response lasting six months or longer (31% of patients with an ongoing response were followed for less than six months).

Common side effects for patients taking Ayvakit were edema (swelling), nausea, fatigue/asthenia (abnormal physical weakness or lack of energy), cognitive impairment, vomiting, decreased appetite, diarrhea, hair color changes, increased lacrimation (secretion of tears), abdominal pain, constipation, rash and dizziness. Ayvakit can cause intracranial hemorrhage (bleeding that occurs inside the skull) in which case the dose should be reduced, or the drug should be discontinued. Ayvakit can also cause central nervous system effects including cognitive impairment, dizziness, sleep disorders, mood disorders, speech disorders and hallucinations. If this happens, depending on the severity, Ayvakit should be withheld and then resumed at the same or reduced dose upon improvement or permanently discontinued.

Health care professionals should advise pregnant women that Ayvakit may cause harm to a developing fetus or newborn baby. Additionally, the FDA advises health care professionals to tell females of reproductive potential, and males with female partners of reproductive potential, to use effective contraception during treatment with Ayvakit and for six weeks after the final dose.

The FDA granted this applicationBreakthrough Therapydesignation, which expedites the development and review of drugs that are intended to treat a serious condition, when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapies. Ayvakit was also grantedFast Trackdesignation, which expedites the review of drugs to treat serious conditions and fill an unmet medical need. Ayvakit receivedOrphan Drugdesignation, which provides incentives to assist and encourage the development of drugs for rare diseases.

The FDA granted approval of Ayvakit to Blueprint Medicines Corporation.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

###

推荐阅读

FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

Fiona Yu专栏 | 沉寂多年的至尊辉瑞,还有并购以外的法宝吗?

2020-01-08

FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

Fiona Yu | 全球20大药企战略分析

2019-12-29

FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

Fiona Yu专栏 | BMS能否东山再起,靠的是O药还是Celgene

2020-01-03

FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

Fiona Yu专栏 | 靠兼并长大的赛诺菲(Sanofi),真正的绝招是啥?

2019-12-19

FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

Fiona Yu专栏 | 默沙东(MSD)能凭K药乘风破浪,霸王再起吗?

2019-12-13

FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

Fiona Yu专栏 | 从不合并的礼来(Lilly),单靠自己究竟能走多远?

2019-10-13 特稿

FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

Fiona Yu专栏 | 化工老大到药企龙头,从诺华Novartis)的转型经验你学到啥?

2019-11-27

FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

Fiona Yu专栏 | 武田Takeda)模式能否帮助亚洲药企杀入国际?

2019-11-20

FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

Fiona Yu专栏 | 百年药企强生(JNJ),能否再走百年?

2019-11-13

FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

Fiona Yu专栏 | 生物链上的江湖,新基(Celgene)是猎人还是猎物?

2019-10-28

FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

Fiona Yu专栏 | 走下神坛后,吉利德(Gilead)有何妙计翻身?

2019-10-22

FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法
FDA批准首个针对胃肠道间质瘤患者罕见突变的靶向疗法

发布者:药时代,转载请首先联系contact@drugtimes.cn获得授权

发表评论

登录后才能评论
分享本页
返回顶部